The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor
Key facts
- Where
- Istanbul, TürkiyeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07358754, who can take part
Where in Türkiye
- Kanuni Sultan Süleyman Training and Research HospitalIstanbul, TürkiyeContact: Zeynep Karakuzu Güngör, M.DTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Kanuni Sultan Suleyman Training and Research Hospital
- Trial code
- NCT07358754
- Record updated
- 15 April 2026
- Original description
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified.Read full original descriptionShow less
The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor (BDNF) Levels and Central Sensitization and Sleep Quality in Patients With Fibromyalgia
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified.
Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.
Inclusion: Female participants aged between 18 and 50 years; Diagnosis of fibromyalgia according to 2016 American College of Rheumatology (ACR) criteria; Symptoms present for at least 3 months; Ability to understand and complete study questionnaires; Provision of written informed consent; For healthy controls:; No diagnosis of fibromyalgia or chronic widespread pain; No known systemic disease.
Exclusion: -.